Pay in 4 interest-free payments of $6.03 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
BCBS Federal Employee Program members experienced dramatic cost increases starting in 2025
Summary: Retatrutide is an investigational triple receptor agonist (GLP-1, GIP, and glucagon) showing promising early weight-loss and metabolic data in Phase 2 trials, but it is not yet approved in the UK and carries notable side effects and safety uncertainties
Countries in regions such as Latin America, Southeast Asia, and parts of Africa are witnessing a surge in obesity prevalence, driven by economic growth and increased adoption of Western food consumption patterns
Some patches may reference GLP-1 support or GLP-1 activation, but these phrases are marketing terms rather than medical ones
.png)
US$ 21.05
US$ 21.37
US$ 20.51
US$ 25.15
US$ 24.50
